CD4 and pneumocystosis: We then aimed to compare this incidence to 1) the natural history rate of PCP in the HIV-infected population, 2) the incidence of PCP in individuals who discontinued prophylaxis with CD4l count >200 cells/μL and 3) the incidence of PCP in individuals who continue prophylaxis with CD4 count <200 cells/μL prior to the availability of HAART.